Astrazeneca plc, of London, reported that a combination of Lynparza (olaparib) and paclitaxel, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival in either the overall population or patients whose tumor tested negative for Ataxia-Telangiectasia mutated protein during the phase III GOLD trial in advanced gastric cancer patients.